UBS Group’s Kite Pharma, Inc. KITE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-46,800
Closed -$2.1M 8306
2016
Q4
$2.1M Hold
46,800
﹤0.01% 2873
2016
Q3
$2.61M Buy
+46,800
New +$2.61M ﹤0.01% 2601

UBS Group's KITE Position: Q4 2017 in Review

UBS Group sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 226,458 shares — an estimated $40.7M sold.

UBS Group first reported a position in KITE in Q4 2014 and held it in 12 quarters. The position peaked at $40.7M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • UBS Group reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • UBS Group sold 226,458 Kite Pharma, Inc. shares in Q4 2017, an estimated $40.7M.
  • UBS Group first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 12 quarters.
  • UBS Group's Kite Pharma, Inc. position peaked at $40.7M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on UBS Group's 13F filing for Q4 2017, filed 14 Feb 2018.